The Oncology Institute, Inc. financials

TOI CIK 0001799191

Source: EDGAR filings · Built 2026-06-04T02:31:06Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow -27.82M -30.37M -40.98M -67.34M -35.56M -717.00K
EBITDA -29.14M -53.83M -71.14M -77.54M -42.52M -5.02M
Working Capital 41.78M 60.20M 108.70M 100.70M 124.26M 1.11M
Net Debt 70.19M 73.58M 86.33M 94.41M -114.99M 11.03M
Operating Margin -7.18% -15.28% -23.75% -32.46% -22.59% -4.37%
Net Margin -12.06% -16.44% -25.62% 0.06% -5.38% -7.64%
Return on Equity (ROE) 385.53% -1801.70% -145.67% 0.12% -10.49% -50.97%
Return on Assets (ROA) -36.81% -37.44% -39.70% 0.06% -5.37% -21.80%
Current Ratio 1.59× 2.15× 4.12× 4.39× 5.17× 1.04×
Debt-to-Equity -6.60× 34.34× 2.10× 0.88× 0.00× 0.42×
Effective Tax Rate 0.22% 0.00% 0.04% 267.03% 5.79% 3.33%
Cash Conversion Ratio 0.41× 0.41× 0.44× -406.29× 2.99× -0.04×
Accruals Ratio -0.22× -0.22× -0.22× 0.24× 0.11× -0.23×
SBC % of Revenue 0.91% 2.83% 5.49% 10.96% 12.09% 0.08%
CapEx Coverage -7.60× -6.93× -7.78× -11.05× -11.35× 0.41×
Free Cash Flow Per Share $-0.30 $-0.40 $-0.56 $-0.84 $-0.54 $-0.01

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/S 0.70× 0.06× 0.47× 0.48× 3.52× 0.33×
P/B 6.52× 2.65× 0.98× 6.86× 2.21×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 502.73M 393.41M 324.24M 252.48M 203.00M 187.51M
Selling, General and Administrative Expense 105.57M 107.83M 113.85M 119.69M 83.36M 41.90M
Operating Income (Loss) -36.08M -60.12M -77.02M -81.95M -45.86M -8.20M
Income Tax Expense (Benefit) -131.00K 0 -36.00K -243.00K -671.00K -493.00K
Net Income (Loss) Attributable to Parent -60.61M -64.66M -83.07M 152.00K -10.93M -14.32M
Earnings Per Share, Basic $-0.54 $-0.71 $-0.92 $0.00 $-0.16 $-0.24
Weighted Average Number of Shares Outstanding, Basic 92.39M 75.04M 73.75M 72.79M 66.23M 59.12M
Earnings Per Share, Diluted $-0.54 $-0.71 $-0.92 $-0.21 $-0.16 $-0.24
Weighted Average Number of Shares Outstanding, Diluted 92.39M 75.04M 73.75M 80.61M 66.23M 59.12M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 900.00K
Assets, Current 112.75M 112.42M 143.49M 130.42M 154.06M 29.72M
Assets 164.66M 172.72M 209.24M 261.67M 203.44M 65.69M
Liabilities, Current 70.96M 52.22M 34.79M 29.72M 29.80M 28.61M
Long-term Debt, Excluding Current Maturities 77.40M 93.13M 86.83M 80.62M 0 6.56M
Liabilities 180.38M 169.13M 152.22M 138.49M 99.28M 37.59M
Stockholders' Equity Attributable to Parent -15.72M 3.59M 57.02M 123.17M 104.16M 28.10M
Common Stock, Shares, Outstanding 98.86M 75.74M 74.15M 73.27M 73.25M 5.75M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities -24.59M -26.54M -36.31M -61.76M -32.68M 508.00K
Payments to Acquire Property, Plant, and Equipment 3.20M 3.79M 4.57M 5.53M 2.85M 1.19M
Net Cash Provided by (Used in) Investing Activities -3.07M 46.21M 62.64M -131.61M -12.15M -8.84M
Payments for Repurchase of Common Stock 0 1.02M 9.00M 0
Net Cash Provided by (Used in) Financing Activities 11.56M -3.49M -6.85M 92.21M 154.01M 11.89M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (TOI CIK 0001799191), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

CTRI

Centuri Holdings, Inc.

MHO

M/I HOMES, INC.

TXNM

TXNM Energy, Inc.